| Oct 22 |
Mainz Biomed restructured operations, implemented cost reductions
|
| Oct 21 |
Mainz Biomed B.V. GAAP EPS of -$0.49, revenue of $520.77M
|
| Oct 21 |
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
|
| Oct 10 |
Mainz Biomed Secures Additional $1.5M Funding
|
| Oct 8 |
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
|
| Oct 1 |
The Covid Era Tech Promises To Reinvent Cancer Treatment
|
| Oct 1 |
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
|
| Sep 20 |
Pfizer Advances On Its Cancer Journey
|
| Sep 18 |
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
|
| Sep 4 |
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
|
